Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018125950) A COMBINATION THERAPY FOR TREATING CANCER
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/125950 International Application No.: PCT/US2017/068619
Publication Date: 05.07.2018 International Filing Date: 28.12.2017
IPC:
A61K 31/352 (2006.01) ,A61K 31/337 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
35
having six-membered rings with one oxygen as the only ring hetero atom
352
condensed with carbocyclic rings, e.g. cannabinols, methantheline
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
335
having oxygen as the only ring hetero atom, e.g. fungichromin
337
having four-membered rings, e.g. taxol
Applicants:
LI, Shiming [US/US]; US
HUANGGANG NORMAL UNIVERSITY [CN/CN]; Huanggang, CN
Inventors:
LI, Shiming; US
Agent:
LU, Bin; US
Priority Data:
15/396,43531.12.2016US
Title (EN) A COMBINATION THERAPY FOR TREATING CANCER
(FR) POLYTHÉRAPIE DESTINÉE AU TRAITEMENT DU CANCER
Abstract:
(EN) Disclosed is a method of treating a subject having non-small cell lung cancer. The method includes administering to the subject a therapeutically effective amount of a composition and the composition contains 5-demethylnobiletin and docetaxel. Compared with the use of docetaxel alone, the method of combining 5-demethylnobiletin and docetaxel had a 4.4 fold increase in inhibiting the growth of human lung cancer cells, and had a 3.05 fold increase in inhibiting tumor growth in human lung cancer cell-engrafted nude mice.
(FR) L'invention concerne une méthode de traitement de patients atteints d'un cancer du poumon non à petites cellules. La méthode comprend l'administration au patient d'une quantité thérapeutiquement efficace d'une composition, la composition contenant de la 5-diméthyl nobilétine et du docétaxel. Par comparaison avec l'utilisation du docétaxel seul, la méthode associant de la 5-diméthyl nobilétine et du docétaxel augmentait de 4,4 fois l'inhibition de la croissance des cellules cancéreuses du poumon humain, et augmentait de 3,05 fois l'inhibition de la croissance tumorale chez la souris nude porteuse d'une greffe de cellules de cancer du poumon humain.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)